Pepkon Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 8

Pepkon General Information

Description

Developer of peptide-based therapeutic candidates in oncology designed to target cancer cell pathways and address the limitations of existing treatments for refractory cancers. The company offers in-house peptide design, chemical optimization, synthesis, and biological testing of drug candidates targeting the TSP-1/CD47 immune checkpoint pathway, enabling oncology researchers and clinical institutions to advance novel cancer immunotherapies.

Contact Information

Website
www.pepkon.fr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 19 chemin de Prunay
  • 78430 Louveciennes
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 19 chemin de Prunay
  • 78430 Louveciennes
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pepkon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC 01-Aug-2024 Completed Generating Revenue
5. Accelerator/Incubator 20-May-2024 Completed Generating Revenue
4. Early Stage VC 01-Jan-2024 Completed Pre-Clinical Trials
3. Accelerator/Incubator 05-Feb-2023 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2023 Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2022 Completed Pre-Clinical Trials
To view Pepkon’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Pepkon Patents

Pepkon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11759496-B2 Compounds and pharmaceutical use thereof in the treatment of cancer Active 10-May-2016
US-20230414702-A1 Compounds and pharmaceutical use thereof in the treatment of cancer Inactive 10-May-2016
US-20190144501-A1 New compounds and pharmaceutical use thereof in the treatment of cancer Active 10-May-2016
EP-3434276-A1 Method and pharmaceutical composition for use in the treatment of cancer Active 06-Jun-2012
EP-3434276-B1 Method and pharmaceutical composition for use in the treatment of cancer Active 06-Jun-2012 C07K14/78
To view Pepkon’s complete patent history, request access »

Pepkon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pepkon Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aloe Private Equity PE/Buyout Minority
Angel (individual) Minority
Matwin Accelerator/Incubator
Paris-Saclay Cancer Cluster Accelerator/Incubator
JML Invest Family Office Minority
You’re viewing 5 of 8 investors. Get the full list »

Pepkon FAQs

  • When was Pepkon founded?

    Pepkon was founded in 2022.

  • Where is Pepkon headquartered?

    Pepkon is headquartered in Louveciennes, France.

  • What is the size of Pepkon?

    Pepkon has 10 total employees.

  • What industry is Pepkon in?

    Pepkon’s primary industry is Drug Discovery.

  • Is Pepkon a private or public company?

    Pepkon is a Private company.

  • What is Pepkon’s current revenue?

    The current revenue for Pepkon is .

  • Who are Pepkon’s investors?

    Aloe Private Equity, , Matwin, Paris-Saclay Cancer Cluster, and JML Invest are 5 of 8 investors who have invested in Pepkon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process